EUVIMEDEUVIMED entdecken
Crossref

TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer

Valentina Cirello iD, Carla Colombo iD, Delfina Tosi iD, Alessandro Manzo iD, Maria Orietta Borghi, Umberto Gianelli iD, Giacomo Gazzano iD, Stefano Ferrero iD, Gianlorenzo Dionigi iD, Luca Persani iD, Laura Fugazzola iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Valentina Cirello und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine and Metabolic Diseases, Endocrine Oncology Unit, IRCCS Istituto Auxologico Italiano, Milan 20149, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Quinolines, Tumor Suppressor Protein p53, Phenylurea Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

No data are available about the possible association of TP53 mutations and the response to multikinase inhibitors (MKIs) in thyroid cancer (TC).

Objective

We evaluated the effect of TP53 mutations on the response to lenvatinib (LEN) in advanced TCs and in vitro models.

Methods

We investigated the molecular profile, including TP53 mutations, of 30 tumor tissues from patients treated with LEN, and tested p53 status by immunohistochemistry. These data were compared with clinical-pathological features, and tumor response to LEN. The response to LEN was also evaluated in TP53-defective and TP53-proficient TC cell lines.

Results

TP53 mutations significantly correlated with a poor response to LEN (P = .005). TP53-mutated patients had a shorter progression-free survival (PFS) (P < .0001) and overall survival (OS) rates (P = .0007). Accordingly, patients harboring altered nuclear p53 protein expression had shorter PFS and OS (P = .0001 and P = .0056, respectively). These data were confirmed in a validation cohort. In accordance with clinical data, TC cell lines with p53 alterations had low or null sensitivity, while those with TP53 wild-type showed different degrees of sensitivity, primarily due to the increased number of tumor cells in G1 phase, consistent with the cytostatic effect of LEN.

Conclusion

We show for the first time in advanced TC that the presence of TP53 alterations is a predictor of poor response to LEN treatment and is associated with worse PFS and OS rates. The evaluation of TP53 mutations/p53 expression might be included in the patient/tumor characterization to be performed before starting an MKI treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsQuinolinesTumor Suppressor Protein p53Phenylurea CompoundsAntineoplastic AgentsHumansMaleFemaleMiddle AgedMutationAgedAdultCell Line, TumorProtein Kinase InhibitorsPrognosisProgression-Free SurvivalTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

TP53advanced thyroid cancerlenvatinibmultikinase inhibitorspoorly differentiated thyroid cancerresistance to MKI

Substanzen

lenvatinibQuinolinesTumor Suppressor Protein p53Phenylurea CompoundsTP53 protein, humanAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Endocrine and Metabolic Diseases, Endocrine Oncology Unit, IRCCS Istituto Auxologico Italiano, Milan 20149, Italy.
  • Department of Pathophysiology and Transplantation, University of Milan, Milan 20122, Italy.
  • Department of Health Sciences, Unit of Human Pathology, Santi Paolo e Carlo Medical School, University of Milan, Milan 20141, Italy.
  • Department of Biotechnology and Translational Medicine, University of Milan, Milan 20133, Italy.
  • Immunorheumatology Research Laboratory, IRCCS Istituto Auxologico Italiano, Milan 20095, Italy.
  • Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza 2023-2027, University of Milan, Milan 20122, Italy.

ORCID-Profile: Valentina Cirello, Carla Colombo, Delfina Tosi, Alessandro Manzo, Umberto Gianelli, Giacomo Gazzano, Stefano Ferrero, Gianlorenzo Dionigi, Luca Persani, Laura Fugazzola

Förderung

  • Italian Ministry of Health

Zitieren

APA

Cirello, V., Colombo, C., Tosi, D., Manzo, A., Borghi, M. O., Gianelli, U., Gazzano, G., Ferrero, S., Dionigi, G., Persani, L., & Fugazzola, L. (2025). TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf056

Vancouver

Cirello V, Colombo C, Tosi D, Manzo A, Borghi MO, Gianelli U, et al. TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf056

BibTeX
@article{Cirello2025,
  author = {Cirello, Valentina and Colombo, Carla and Tosi, Delfina and Manzo, Alessandro and Borghi, Maria Orietta and Gianelli, Umberto and Gazzano, Giacomo and Ferrero, Stefano and Dionigi, Gianlorenzo and Persani, Luca and Fugazzola, Laura},
  title = {TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf056}
}
Kostenlos starten →